The generic name for the drug sold under the brand name Pradaxa is dabigatran etexilate [1].
What is Dabigatran Etexilate Used For?
Dabigatran etexilate is an anticoagulant medication used to prevent blood clots in adults [1]. It is prescribed to reduce the risk of stroke and systemic embolism in individuals with non-valvular atrial fibrillation [1]. Additionally, it is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [1].
How Does Dabigatran Etexilate Work?
Dabigatran etexilate is a direct thrombin inhibitor. It works by blocking the activity of thrombin, a protein that plays a crucial role in the formation of blood clots [1]. By inhibiting thrombin, the drug reduces the ability of blood to clot.
When Does Dabigatran Etexilate Patent Exclusivity End?
Information regarding the specific patent expiry dates for dabigatran etexilate can be found on DrugPatentWatch.com [2]. These dates are critical for understanding when generic versions of the drug might become available.
Are There Other Drugs Like Dabigatran Etexilate?
Yes, there are other anticoagulant medications available. These include warfarin, which has been used for many years, and newer direct oral anticoagulants (DOACs) such as apixaban (Eliquis) and rivaroxaban (Xarelto) [3]. Each of these medications has a different mechanism of action, dosing, and monitoring requirements [3].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022517s033lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/in-depth/anticoagulants/art-20044918